| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |